The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Cellular And Molecular Aspects Of Mammographic Density As A Predictor Of Breast Cancer Risk In Pseudo-orthotopic Mammatrophic Environment
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
High mammographic density (MD), or denser breast tissue on mammogram, is associated with greater breast cancer risk. Despite this, the basis for its increased risk is poorly understood. This study assesses the effect of high density breast tissue transferred from high risk women at time of mastectomy into tissue engineering chambers in mice. Changes in the connective tissue harvested from the chamber were examined with specialized imaging, laboratory stains and molecular analysis.
Clinicopathological Characterisation Of Male Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
Male Breast Cancer is an uncommon and poorly understood disease. Due to its low frequency, there is a paucity of studies with large numbers of patients. Our aim will be to establish one of the largest worldwide databases of Male Breast Cancer. This will allow us to more thoroughly investigate clinical, pathological and molecular characteristics of male breast cancer, improve treatment of these patients and potentially develop novel and innovative strategies for treatment of female breast cancer.
Genetic Variants, Phenotypic Spectrum And Breast Cancer Risk Associated With Germline Mutations In PALB2: Identifying Female PALB2 Mutation Carriers At The Time Of Diagnosis
Funder
National Health and Medical Research Council
Funding Amount
$45,093.00
Summary
Population studies of female breast cancer (BC) show only a small proportion of familial aspects of BC can be explained by current knowledge of its causes. Women carrying PALB2 mutations who also have a strong family history of BC are of increased risk of BC. Our work will further define the risks and devise criteria to identify women most likely to carry PALB2 mutations. This will help prioritize testing, classify PALB2 variants and provide appropriate clinical management to carriers.
Tumour-associated Macrophages (TAMs) And Their Role In Breast Cancer Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$72,537.00
Summary
Tumour-associated macrophages (TAMs) have been implicated in breast cancer spread. Tumour cell behaviour is influenced by the surrounding environment. This study will determine the relationship of TAMs to other cell populations, if the expression of the enzyme, u-PA, in non-tumour cells within the tumour environment is important for breast cancer spread, and whether TAM precursor white blood cells home to the primary tumour and-or to the site of tumour spread before the arrival of tumour cells.
Transient Receptor Potential Calcium Channels In Breast Cancer Cell Proliferation, Apoptosis And Invasiveness
Funder
National Health and Medical Research Council
Funding Amount
$104,018.00
Summary
Calcium is a highly regulated signal used by cells to control processes such as growth and division, cell death and motility. Calcium channels let calcium into the cells, and specific calcium channel types are overexpressed in cancers, including those of the prostate and breast. In this research, we will assess the role of specific calcium permeable channels known as TRPs in breast cancer and the consequences of their inhibition on breast cancer cell growth and survival.